133 related articles for article (PubMed ID: 8680655)
1. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone.
Krouse RS; Royal RE; Heywood G; Weintraub BD; White DE; Steinberg SM; Rosenberg SA; Schwartzentruber DJ
J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):272-8. PubMed ID: 8680655
[TBL] [Abstract][Full Text] [Related]
2. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment.
Weijl NI; Van der Harst D; Brand A; Kooy Y; Van Luxemburg S; Schroder J; Lentjes E; Van Rood JJ; Cleton FJ; Osanto S
J Clin Oncol; 1993 Jul; 11(7):1376-83. PubMed ID: 8315436
[TBL] [Abstract][Full Text] [Related]
3. Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma.
Scalzo S; Gengaro A; Boccoli G; Masciulli R; Giannella G; Salvo G; Marolla P; Carlini P; Massimini G; Holdener EE
Eur J Cancer; 1990; 26(11-12):1152-6. PubMed ID: 2149997
[TBL] [Abstract][Full Text] [Related]
4. Thyroid dysfunction associated with immunotherapy for patients with cancer.
Schwartzentruber DJ; White DE; Zweig MH; Weintraub BD; Rosenberg SA
Cancer; 1991 Dec; 68(11):2384-90. PubMed ID: 1933775
[TBL] [Abstract][Full Text] [Related]
5. The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma.
MacFarlane MP; Yang JC; Guleria AS; White RL; Seipp CA; Einhorn JH; White DE; Rosenberg SA
Cancer; 1995 Feb; 75(4):1030-7. PubMed ID: 7842405
[TBL] [Abstract][Full Text] [Related]
6. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma.
Guleria AS; Yang JC; Topalian SL; Weber JS; Parkinson DR; MacFarlane MP; White RL; Steinberg SM; White DE; Einhorn JH
J Clin Oncol; 1994 Dec; 12(12):2714-22. PubMed ID: 7989949
[TBL] [Abstract][Full Text] [Related]
7. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
Rosenberg SA; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
JAMA; 1994 Mar 23-30; 271(12):907-13. PubMed ID: 8120958
[TBL] [Abstract][Full Text] [Related]
8. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
9. Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-alpha.
Jacobs EL; Clare-Salzler MJ; Chopra IJ; Figlin RA
J Immunother (1991); 1991 Dec; 10(6):448-55. PubMed ID: 1768679
[TBL] [Abstract][Full Text] [Related]
10. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
Sosman JA; Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; O'Boyle K; Fisher RI; Boldt DH; Doroshow J
J Clin Oncol; 1993 Aug; 11(8):1496-505. PubMed ID: 8336188
[TBL] [Abstract][Full Text] [Related]
11. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
12. Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin 2.
Spanknebel K; Cheung KY; Stoutenburg J; Hurst-Wicker K; Hesdorffer C; Deraffele G; Kaufman HL
Ann Surg Oncol; 2005 May; 12(5):381-90. PubMed ID: 15915372
[TBL] [Abstract][Full Text] [Related]
13. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation.
Miyake H; Kurahashi T; Yamanaka K; Kondo Y; Muramaki M; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2010; 28(5):515-9. PubMed ID: 19914105
[TBL] [Abstract][Full Text] [Related]
14. [Hyperdynamic hemodynamics following high-dose interleukin 2-interferon alpha therapy in patients with metastatic renal cell carcinoma. Immunotherapy as a clinical sepsis model?].
Finck-Seelen ; Lampert R; Brandt L
Anaesthesist; 1996 Dec; 45(12):1171-8. PubMed ID: 9065251
[TBL] [Abstract][Full Text] [Related]
15. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
Rosenberg SA; White DE
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
[TBL] [Abstract][Full Text] [Related]
16. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
Rosenberg SA; Yannelli JR; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
J Natl Cancer Inst; 1994 Aug; 86(15):1159-66. PubMed ID: 8028037
[TBL] [Abstract][Full Text] [Related]
17. Effect of calcium replacement on the hemodynamic changes associated with high dose interleukin-2 therapy.
Redman BG; Flaherty L; Martino S; Kraut M; Wisniewski C; Valdivieso M; Bander JJ
Am J Clin Oncol; 1992 Aug; 15(4):340-3. PubMed ID: 1514532
[TBL] [Abstract][Full Text] [Related]
18. Iodinated Contrast Media-Induced Thyroid Dysfunction in Euthyroid Nodular Goiter Patients.
Kornelius E; Chiou JY; Yang YS; Lo SC; Peng CH; Lai YR; Huang CN
Thyroid; 2016 Aug; 26(8):1030-8. PubMed ID: 27315873
[TBL] [Abstract][Full Text] [Related]
19. Transient thyrotoxicosis and persistent hypothyroidism due to acute autoimmune thyroiditis after interleukin-2 and interferon-alpha therapy for metastatic carcinoma: a case report.
Sauter NP; Atkins MB; Mier JW; Lechan RM
Am J Med; 1992 Apr; 92(4):441-4. PubMed ID: 1558092
[TBL] [Abstract][Full Text] [Related]
20. Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer.
Koretz MJ; Lawson DH; York RM; Graham SD; Murray DR; Gillespie TM; Levitt D; Sell KM
Arch Surg; 1991 Jul; 126(7):898-903. PubMed ID: 1854252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]